Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
